Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by P Garrido
Words (Excluding Tãtle and Authors: 300) Title: Cost-Effectiveness Analysis of Nivolumab for the Treatment of Second-Line Advanced Squamous Non-Small Cell Lung Cancer (Nsclc) in Spain
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Levosimendan Preconditioning in Patients Undergoing Elective Cardiac Surgery With Poor Ejection Fraction. Preliminary Results.
Journal of Cardiothoracic Surgery
Cardiology
Cardiovascular Medicine
Medicine
Pulmonary
Respiratory Medicine
Surgery
Related publications
Cost-Effectiveness of First-Line Therapy for Advanced Non-Small Cell Lung Cancer (Nsclc)
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
PCN37 Cost-Minimization Analysis of Second-Line Chemotherapy for Non-Small-Cell Lung Cancer (NSCLC)
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
P1.04-29 Second or Third Line Nivolumab Versus First Line Nivolumab in Patients With Previously Treated Advanced Non Small Cell Lung Cancer (NSCLC)
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Pharmacoeconomic Study of Pembrolizumab and Nivolumab in the Second Line of Therapy of Advanced Non-Small Cell Lung Cancer
Effective Pharmacotherapy
Cost Effectiveness of Treatment With New Agents in Advanced Non-Small-Cell Lung Cancer
PharmacoEconomics
Health Policy
Public Health
Occupational Health
Pharmacology
Environmental
Effectiveness of First-Line Treatments in Metastatic Squamous Non-Small-Cell Lung Cancer
Current Oncology
Oncology
Pcn152 - Cost Effectiveness of Alectinib in the First Line Treatment of Advanced Alk-Positive Non-Small Cell Lung Cancer in Turkey
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Docetaxel Monotherapy as Second-Line Treatment for Pretreated Advanced Non-Small Cell Lung Cancer Patients
Korean Journal of Internal Medicine
Internal Medicine
Cost-Effectiveness of First-Line Erlotinib in Patients With Advanced Non-Small-Cell Lung Cancer Unsuitable for Chemotherapy
BMJ Open
Medicine
